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Abstract
Flavan-3-ols are a subclass of flavonoids found in a variety of foods including teas. The effects of flavan-3-ols on the risk of metabolic syndrome
(MetS) have been investigated, generally focusing on tea catechins or individual flavan-3-ol rich foods, but there is little information on dietary
flavan-3-ols intake and risk of MetS in population-based studies. In this cross-sectional study, we examined the association between dietary flavan-3-ols
intake and the risk of MetS in Korean adults. Subjects comprised 1,827 men and 2,918 women aged 20-69 years whose data was included in
the 2008 Korean National Health and Nutrition Examination Survey. This survey was conducted between January 2008 and December 2008. Total
flavan-3-ols intakes were calculated from 24-hour dietary recalls using a flavonoids database. Thirty percent of the male subjects and 24% of the
female subjects were reported as having MetS. In the female subjects, flavan3-ols intake was inversely associated with the risk of MetS after adjusting
for potential confounders (5th vs. 1st quintile, OR = 0.64, 95% CI = 0.45-0.91, P for trend = 0.384). The main food source of flavan-3-ols was green
tea followed by apples and grapes. Among MetS components, flavan3-ols intake was inversely associated with the risk of high blood pressure after
adjusting for potential confounders (5th vs. 1st quintile, OR = 0.64, 95% CI = 0.45-0.90, P for trend = 0.005). No significant association  between
flavan-3-ols intake and risk of MetS was found in the male subjects. After stratified analysis by obesity (BMI ≥25 or BMI < 25), however, flavan3-ols
intake was inversely related to the risk of hypertension in non-obese men. These results suggest that dietary flavan-3-ols intake may have beneficial
effects on MetS risk by reducing the risk of hypertension. The effects of flavan-3-ols intake dependent on obesity need further investigation. 
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Introduction10)
Flavonoids are a class of plant secondary metabolites and are 
the most common group of polyphenolics in the human diet. 
According to their chemical structure, flavonoids are classified 
into several groups including flavonols, flavones, flavan-3-ols, 
flavanones, anthocyanidins, and isoflavonoids. Differences in the 
chemical structures of flavonoid subclasses alter their biological 
efficacy and bioavailability [1,2]. Flavan-3-ols are the collective 
term for the catechin group of compounds that have a 2-phenyl- 
3,4-dihydro-2H-chromen-3-ol skeleton. Catechin, epigallocatechin, 
epicatechin, epicatechin 3-gallate, epigallocatechin 3-gallate (EGCG), 
theaflavin, thearubigins, theaflavin-3,3-digallate, theaflavin-3- 
gallate, theaflavin-3’-gallate, gallocatechin, and catechin 3-gallate 
are included in flavan-3-ols. Food sources of flavan-3-ols include 
apples, hops, tea, beer, wine, fruit juice, and black tea [3]. 
Metabolic syndrome (MetS) is characterized by a clustering of 
metabolic abnormalities including abdominal obesity, hyperglycemia, 
hypertension, and dyslipidemia [4]. MetS is associated with 
developing type 2 diabetes, cardiovascular disease, and all-cause 
mortality [5,6]. Based on the 2005 Korean National Health and 
Nutrition Examination Survey (KNHANES), the prevalence of 
MetS in men and women was 32.9% and 31.8%, respectively. 
MetS is a complicated interaction between genetic, metabolic, 
and environmental factors, in which diet is a potent modifiable 
environmental factor. A number of foods, nutrients, and dietary 
patterns have been reported to be associated with MetS [7-9]. 
In recent years the effects of flavan-3-ols on the risk of MetS 
have been investigated. Green tea is rich in polyphenols, about 
70% of which are catechins. Tea catechins have shown a relation 
with reduced serum cholesterol, serum triacylglycerol, and visceral 
fat area in animal studies [10-12]. Several epidemiological studies 
also have reported the beneficial effects of green tea consumption 
against cardiovascular disease risk [13-15]. Flavan-3-ols rich 
foods such as fruits, red wine, cocoa, and black tea also have 
been shown to reduce the risk of MetS or its components in 
human studies [16-19]. However, to our knowledge, no study 
has investigated the association of total flavan-3-ols intake from 
various kinds of flavan-3-ols [catechin, epigallocatechin, epicatechin, 
epicatechin 3-gallate, epigallocatechin 3-gallate (EGCG), theaflavin, 
thearubigins, theaflavin-3,3-digallate, theaflavin-3-gallate, theaflavin- 
3’-gallate, gallocatechin, and catechin 3-gallate] and the risk of 
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MetS. Therefore, we examined the association between total 
flavan-3-ols intake and risk of MetS and its components (high 
blood pressure, hyperglycaemia, abdominal obesity, low HDL 
cholesterol, and hypertriglyceridaemia) in Korean adults. 
Subjects and Methods
Study population
The Korean National Health and Nutrition Examination Survey 
(KNHANES) is a series of surveys designed to assess the health 
and nutritional status of the Korean population. The KNHANES 
began in 1998 and was conducted in 1998, 2001, and 2005. Since 
2007, the KNHANES has been conducted annually. The 
KNHANES consists of a health interview, health examination 
(physical examination, clinical measurements, and tests), and a 
dietary interview. The subjects of the KNHANES were aged ≥
1 year and were from stratified multistage samples of the South 
Korean population from multiple geographic areas, ages, and of 
both genders. 
A total of 8,631 people participated in the 2008 KNHANES. 
We excluded subjects aged < 20 years or > 69 years (n = 3339), 
those who did not take the health examination (n = 310), those 
who reported implausible dietary intakes (< 500 kcal/d or > 4500 
kcal) (n = 79), and those who did not have data on waist 
circumference, blood pressure, blood glucose, triglycerides, or 
high density lipoprotein (HDL)-cholesterol (n = 158). Finally, 
4,745 subjects aged 20-69 years were included in the analysis. 
This study was approved by the Institutional Review Board (IRB) 
of Ewha Womans University. Written informed consent was 
obtained from all subjects. 
General characteristics, anthropometrics, and biochemical 
variables
A structured questionnaire including information on demo-
graphics, education, smoking, alcohol intake, exercise, medical 
history, and female reproductive history was administered by 
trained interviewers. Height was measured within 0.1 cm and 
weight was measured with a metric weight scale to the nearest 
0.01 kg in light clothing without shoes. Body mass index (BMI) 
was calculated as weight (kg)/ height (m
2). Waist circumference 
(WC) was measured according to the WHO guideline at the end 
of a normal expiration. Blood pressure measurements were taken 
three times, and the average of the second and third mea-
surements for systolic blood pressure and diastolic blood pressure 
were used (Baumanometer, New York, USA). Blood samples 
were collected in the morning after at least ten hours of fasting 
and all biochemical markers were analyzed on the same day. 
Plasma total cholesterol, triglycerides, glucose, and high density 
lipoprotein (HDL) cholesterol were measured by an ADVIA1650 
Automatic Analyzer (Siemens, New York, USA).
Diagnosis of metabolic syndrome 
Metabolic syndrome was diagnosed if the subjects had three 
or more risk determinants according to the modified National 
Cholesterol Education Program Adult Treatment Panel III 
guidelines [20] using the standard waist circumference for 
Koreans [21]. The determinants were as follows: 1) a waist 
circumference  ≥90 cm for men and ≥85 cm for women; 2) 
a plasma TG concentration of 150 mg/dL; 3) a plasma 
concentration of HDL-C < 40 mg/dL for men and < 50 mg/dL 
for women; 4) a systolic BP ≥130 mmHg and diastolic BP ≥
85 mmHg; and 5) a fasting plasma glucose concentration ≥100 
mg/dL.
Dietary assessment and flavonoid database
Trained dietitians interviewed each subject to collect dietary 
data through 24 hr dietary recalls. The daily flavan-3-ols intake 
from foods was estimated using a flavonoid database. Since a 
national nutrient database for flavonoids is not available in Korea, 
we constructed the flavonoid database for plant foods consumed 
by 8,631 subjects in the 2008 KNHANES from January 2008 
to December 2008 using the United States Department of 
Agriculture (USDA) Flavonoid Content of Food Database [22], 
the Japan Functional Food Factor Database [23], and the Rural 
Development Administration Food Functional Composition 
Table [24]. For Korean foods with flavonoid analytic data, only 
data satisfied with a certain quality by the USDA nutrient data 
evaluation system were added to the database. Flavonoid contents 
for combination foods were calculated using standard recipes. 
If we could not find the same plant in other countries’ database, 
we used data of a similar plant, based on species, genus, nutrients, 
shape, and color. The subjects of the 2008 KNHANES consumed 
1,549 plant foods based on 24hr dietary recall data. The flavonoid 
database with 1,317 food items covered 85% of the plants foods 
consumed by the subjects of the 2008 KNHANES. When 1,549 
foods were sorted by intake amounts from high to low, we 
defined the foods ranked ≤ the 95th percentile as ‘commonly 
consumed food’. A total of 922 plant foods were classified into 
the commonly consumed food group, of which the flavonoids 
database covered 96%. Flavan-3-ols intake was the sum of catechin, 
epigallocatechin, epicatechin, epicatechin 3-gallate, epigallocatechin 
3-gallate (EGCG), theaflavin, thearubigins, theaflavin-3,3-digallate, 
theaflavin-3-gallate, theaflavin-3’-gallate, gallocatechin, and catechin 
3-gallate intakes.
Statistical analysis
Nutrient intakes were adjusted for total energy intake by the 
residual method. The subjects were categorized into quintiles by 
dietary flavan-3-ols intake. The Student’s t-test and the Chi- 
square test were applied to determine differences in means and 
the distribution between the MetS group and control group. The 70 Flavan-3-ols intake and metabolic syndrome
general linear model (GLM) and Cochran Mantel Haenzel analysis 
were used to determine the linear trends across the flavan-3-ols 
intake groups. Non-conditional logistic regression analysis was 
applied to obtain the odds ratios (ORs) and corresponding 95% 
confidence intervals for MetS. Potential confounders were 
identified by examining the differences in means and distri-
butions between the MetS group and control group. The variables 
that showed significantly different means or distributions between 
the MetS group and control group or showed significant linear 
trends across quintiles of flavan3-ols were considered as potential 
confounders and adjusted in the analyses. Three different models 
were applied to examine the associations of flavan-3-ols intake 
and MetS. Age and BMI were adjusted as confounders in the 
first model, and potential confounders except dietary factors were 
further adjusted in the second model. The final model addi-
tionally adjusted for dietary factors such as intakes of total 
energy, fat, fiber, and carbohydrate. All statistical analyses were 
performed using the SAS software (version 9.1 SAS Institute 
Inc., Cary, NC, USA), and P values < 0.05 were considered 
significant.
Results
The numbers of subjects for 20-29, 30-39, 40-49, 50-59, 60-69 
years were 606, 1144, 1094, 966, and 935, respectively. Men 
made up 39% of the total subjects, and 30% of the male subjects 
and 24% of the female subjects were diagnosed as having MetS. 
Estimated means of daily total flavan3-ols intake for the men 
and women were 30.0 mg/d and 22.5 mg/d, respectively. The 
general characteristics of subjects are shown in Table 1. The 
means for age and BMI in the MetS group were higher than 
those in the control group for both male and female subjects. 
Education levels were higher in the control group than the MetS 
group for both the male and female subjects. In the male subjects, 
the mean intakes of energy, carbohydrate, fat, protein, and 
vegetables were higher in the control group than in the MetS 
group. There were no significant differences in flavan3-ols intake. 
In the female subjects, the proportions of current drinkers 
(defined as drinking alcohol more than once a month), and 
vitamin/mineral supplement use were higher in the control group 
than in the MetS group. In addition, mean intakes of energy, 
fat, protein, fruits, and flavan3-ols were higher in the control 
group than in the MetS group. The mean intakes of epigallo-
catechin, epicatechin, epicatechin 3-gallate, and EGCG were 
higher in the control group than in the MetS group. 
To determine potential confounding factors, the distributions 
of selected characteristics were examined across quintiles of 
flavan-3-ol intake as shown in Table 2. In the male subjects, 
functional food use (%) and intakes of carbohydrate, fiber, and 
fruits increased across the quintiles of flavan3-ol intake. 
Conversely, regular exercisers (%) and intakes of energy and 
vegetables decreased across the quintiles of flavan3-ols intake. 
In the female subjects, height, current drinkers (%), multivitamin 
users (%) and intakes of carbohydrate, fiber, and fruits increased 
across the quintiles of flavan3-ol intake, but current smokers (%) 
and intakes of energy and vegetables decreased across the 
quintiles of flavan3-ols intake. 
The top ten foods contributing flavan-3-ols in the diets of the 
male and female subjects are shown in Table 3. The main food 
source of flavan-3-ols was green tea followed by grapes, apples, 
and beer in the male subjects. In the females, green tea was the 
main food source of flavan-3-ols followed by apples, grapes, and 
pears.
The relationships between flavan-3-ols intake and the risk of 
MetS and MetS components are given in Table 4. No significant 
association between flavan-3-ols intake and the risk of MetS was 
found in male subjects. In the female subjects, flavan3-ols intake 
was inversely associated with the risk of MetS after adjusting 
for potential confounders (5th vs. 1st quintile, OR = 0.64, 95% 
CI = 0.45-0.91, P for trend = 0.384). When associations between 
flavan3-ols and each MetS component were determined, 
flavan3-ols intake was inversely associated with the risk of high 
blood pressure in female subjects after adjusting for potential 
confounders (5th vs. 1st quintile, OR = 0.64, 95% CI = 0.45-0.90, 
P for trend = 0.005). 
To evaluate if the relationship between flavan3-ols intake and 
MetS risk was different according to the presence of obesity, 
a stratified analysis was applied based on BMI ≥25 or BMI 
< 25, as shown in Fig. 1 and 2. The proportions of obese subjects 
with BMI ≥ 25 were 37% and 28% of the male and female 
subjects, respectively. In the male subjects, flavan3-ols intake 
was inversely related to the risk of hypertension only in 
non-obese men. Among the female subjects, flavan3-ols intake 
was inversely associated with MetS risk after adjusting for 
potential confounders only in obese women. Among the 
components of MetS, flavan3-ols were inversely related to risks 
of hypertension and hyperglycaemia only in obese women. 
However, no significant relationships were found in non-obese 
women. 
Discussion
In the present cross-sectional study, the relationship between 
flavan-3-ols intake and risk of MetS was investigated in male 
and female adult populations. Flavan-3-ols intake was not found 
to be related to the risk of MetS among the male subjects. Among 
the female subjects, flavan-3-ols intake was inversely associated 
with the risk of MetS. In particular, among the MetS components, 
flavan3-ols intake was inversely related to the risk of hyper-
tension among the female subjects. After stratified analysis by 
obesity, flavan3-ols intake was inversely related to the risk of 
hypertension only in non-obese men. Among the female subjects, 
flavan3-ols intake was also inversely associated with risks of 






Control MetS Control MetS
N 1286 541 2230 688
Age (yr) 44.5 ± 13.6
2) 50.5 ± 11.4 < 0.0001 42.2 ± 12.4 55.0 ± 11.1 < 0.0001
Height (cm) 169.8 ± 6.6 168.7 ± 6.3 0.001 157.8 ± 6 155.4 ± 5.7 < 0.0001
Weight (kg) 67.3 ± 9.9 74.1 ± 10.1 < 0.0001 56.0 ± 7.7 63.3 ± 9.1 < 0.0001
BMI (kg/m
2) 23.3 ± 2.8 26.0 ± 2.7 < 0.0001 22.5 ± 2.9 26.2 ± 3.2 < 0.0001
Waist circumference (cm) 82.2 ± 7.9 91.2 ± 7.1 < 0.0001 76.3 ± 8.3 88.1 ± 7.9 < 0.0001
Systolic BP (mmHg) 114.6 ± 14 124.9 ± 15.2 < 0.0001 107.1 ± 13.7 126.2 ± 18.2 < 0.0001
Diastolic BP (mmHg) 75.6 ± 9.8 82.9 ± 10.9 < 0.0001 70.2 ± 9.7 79.3 ± 10.7 < 0.0001
Cholesterol (mg/dl) 183.4 ± 33.5 195.9 ± 35.8 < 0.0001 182.7 ± 33.7 200.3 ± 38.9 < 0.0001
HDL-cholesterol (mg/dl) 47.3 ± 9.6 39.8 ± 7.9 < 0.0001 52.9 ± 10.7 43.1 ± 8.4 < 0.0001
Triglyceride (mg/dl) 122.2 ± 77.7 247.9 ± 193.4 < 0.0001 90.8 ± 59.6 188.9 ± 114.5 < 0.0001
Fasting glucose (mg/dl) 93.9 ± 15.6 113.6 ± 29.8 < 0.0001 91.3 ± 14.8 112.2 ± 34.7 < 0.0001
Insulin (μIU/ml) 8.8 ± 4.4 11.6 ± 6 < 0.0001 9.0 ± 4.3 12.6 ± 10.2 < 0.0001
HOMA-IR 2.0 ± 1.2 3.2 ± 2 < 0.0001 2.0 ± 1.1 3.5 ± 3.2 < 0.0001
Education, N (%)
  Elementary 184 (14.4) 103 (19.1) 0.0003 410 (18.4) 371 (54) < 0.0001
  Middle 176 (13.7) 91 (16.9) 226 (10.1) 105 (15.3)
  High 478 (37.3) 210 (38.9) 900 (40.4) 167 (24.3)
  College 443 (34.6) 136 (25.2) 692 (31.2) 44 (6.4)
Smoking, N (%)
  Smoker 595 (46.5) 232 (43) 0.004 129 (5.8) 38 (5.5) 0.247
  Past-smoker 449 (35.1) 231 (42.8) 130 (5.8) 29 (4.2)
  Non-smoker 237 (18.5) 77 (14.3) 1,967 (88.4) 620 (90.3)
Current drinker (%) 75.5 73.6 0.403 45.2 31.6 < 0.0001
Regular exerciser (%) 62.8 58.0 0.055 55.6 54.8 0.725
Multivitamin user (%) 15.3 17.4 0.319 24.8 18.6 0.003
Functional food use (%) 15.8 16.6 0.870 25.8 26.2 0.965
Energy (kcal/day) 2,174.3 ± 738.3
2) 2,067.9 ± 694.7 0.004 1,636.6 ± 593.4 1,537.5 ± 545.5 < 0.0001
Carbohydrates (g/day) 340.3 ± 112.9 329.0 ± 104.5 0.046 279.7 ± 103.4 278.3 ± 99.8 0.782
Fat (g/day) 43.2 ± 29.5 36.2 ± 24.9 < 0.0001 32.3 ± 23.6 23.3 ± 17.8 < 0.0001
Protein (g/day) 78.3 ± 34.8 73.2 ± 33.1 0.004 58.2 ± 27.2 52.7 ± 25.7 < 0.0001
Fiber (g/day) 8.1 ± 4.8 8.0 ± 4.4 0.420 7.1 ± 4.8 7.0 ± 5.4 0.695
Vegetable (g/day) 410.1 ± 260.7 380.6 ± 225.1 0.022 318.4 ± 225.4 318.3 ± 210.9 0.994
Fruit (g/day) 152.5 ± 286.9 147.0 ± 296.2 0.713 202.8 ± 295.2 167.2 ± 265.3 0.005
Antocyanin (mg/day) 24.7 ± 41.4 28.3 ± 62.9 0.158 25.8 ± 47.3 26.6 ± 42.8 0.687
Flavan-3-ols (mg/day) 30.7 ± 105 28.3 ± 90.2 0.634 24.8 ± 74.2 14.9 ± 53.2 0.001
  Catechin 4.43 ± 11.29 3.54 ± 9.45 0.106 3.91 ± 9.78 3.29 ± 10.28 0.148
  Epigallocatechin 4.19 ± 17.89 3.99 ± 15.38 0.817 3.11 ± 11.96 1.63 ± 8.51 0.003
  Epicatechin 5.62 ± 12.70 4.84 ± 10.45 0.213 6.21 ± 12.31 4.67 ± 11.23 0.004
  Epicatechin 3-gallate 2.92 ± 13.02 2.78 ± 11.31 0.817 2.03 ± 8.73 1.11 ± 6.58 0.011
  Epigallocatechin 3-gallate 12.74 ± 61.63 12.26 ± 53.18 0.875 8.36 ± 40.50 4.01 ± 29.17 0.009
  Theaflavin 0.004 ± 0.05 0.004 ± 0.04 0.937 0.02 ± 0.31 0.001 ± 0.01 0.239
  Thearubigins 0.43 ± 4.27 0.57 ± 4.65 0.552 0.97 ± 16.39 0.07 ± 0.58 0.169
1) B M I ,  b o d y  m a s s  i n d e x ;  B P ,  b lo o d  p r e s s u r e ;  H D L ,  h ig h - d e n s i t y  l ip oprotein;  HOMA-IR,  homeostasis  model  assessment  estimate  of  insulin resistance
2) Mean ± SD
Table 1. Characteristics of subjects with and without metabolic syndrome (MetS) 
potential confounders only in obese women. The present findings 
suggest that flavan3-ols intake may have beneficial effects on 
the risk of MetS by reducing hypertension risk, and the effects 
of flavan3-ols may be different depending on the presence or 
absence of obesity
Daily flavan-3-ols intake was estimated by 24-hr dietary recalls 
in the present study. The estimated means of daily flavan3-ols 
intake for men and women were 30.0 mg/d and 22.5 mg/d, 
respectively, which are lower than daily flavan3-ols intakes 
reported in other countries [25-27]. The main sources of flavan- 72 Flavan-3-ols intake and metabolic syndrome
N Male (1,827)  Female (2,918)
Food % of intake
1) % of Acc
2) Food % of intake % of Acc
Green tea 67.02 67.02 Green tea 47.86 47.86
Grape 8.52 75.54 Apple 15.60 63.46
Apple 6.99 82.53 Grape 13.80 77.26
Beer 6.08 88.61 Pear 6.27 83.53
Pear 4.02 92.63 Peach 4.53 88.06
Peach 2.80 95.43 Black Tea 3.64 91.70
Black tea 0.89 96.32 Beer 2.96 94.66
Banana 0.84 97.16 Banana 1.28 95.94
Coffee 0.56 97.72 Strawberry 0.94 96.88
Strawberry 0.55 98.27 Wine 0.63 97.51
1) %  of  total  flavan-3-ols  intake
2) Acc  stands  for  Accumulation 






Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q5
N 348 381 365 365 365 580 587 583 584 582
Median 0 0.2 0.6 9.3 61.2 0 0.1 0.9 11.4 47.2
Age (yrs) 46.3 47.5 45.5 46.5 45.4 0.159 46.9 44.7 45.4 44.3 44.9 0.0004
Height (cm) 169.2 168.8 169.3 169.7 170.5 0.0004 156.6 157.2 157.1 157.8 157.7 < 0.0001
Weight (kg) 69.0 68.6 69.0 69.1 71.1 0.0002 58 57.7 57.3 57.9 57.6 0.735
BMI (kg/m
2) 24.1 24.0 24.0 23.9 24.4 0.029 23.6 23.4 23.3 23.3 23.2 0.027
Current smoker (%) 42.1 51.2 55.4 39.5 39.7 0.483 7.1 6.3 5.5 4.6 5.2 0.333
Current drinker (%) 77.0 76.3 70.8 74.5 76.1 0.631 35.9 42.7 42.4 44.3 44.7 0.003
Regular exerciser (%) 69.3 58.8 56.4 61.1 61.9 0.150 56.0 56.4 54.2 54.6 55.8 0.741
Multivitamin user (%) 14.4 13.4 15.3 18.6 17.8 0.711 18.1 19.3 23.5 28.1 28.0 0.001
Functional food use (%) 10.3 13.9 15.6 18.4 21.9 0.010 21.6 23.0 28.3 29.3 27.3 0.224
Energy (kcal/day) 1,916.0 2,051.6 2,155.3 2,191.7 2,397.8 < 0.0001 1,418.1 1,527.8 1,649.9 1,622.1 1,850.9 < 0.0001
Carbohydrates, energy adjusted (g/day) 283.8 285.6 294.0 283.1 286.9 0.924 279.6 288.9 288.1 290.4 307.3 < 0.0001
Fat, energy adjusted (g/day) 28.8 28.5 30.8 29.6 27.5 0.016 29.3 30.6 34.2 32.4 30.4 0.251
Fiber, energy adjusted (g/day) 7.1 6.9 6.3 7.0 7.5 0.003 7.1 7.0 7.2 7.4 8.2 < 0.0001
Vegetable (g/day) 390.5 404.1 397.7 395.4 417.5 0.173 315.3 325.7 324.0 313.1 314.9 0.534
Fruit (g/day) 56.5 62.6 63.5 184.5 388.2 < 0.0001 67.0 66.2 133.7 231.8 474.3 < 0.0001
BMI,  body  mass  index;  Q,  quintile
Table 2. Selected characteristics of subjects according to quintiles of flavan-3-ols intake
3-ols were green tea, apples, grapes, pears, beer, and peaches 
in the present study. Intakes of flavan-3-ols in Australia, 
Denmark, and the Netherlands were 422 mg/d, 148 mg/d, and 
145 mg/d, respectively. The main sources of flavan-3-ols were 
black tea, fruits, and red wine in the three countries [25]. 
Estimated daily flavan-3-ols intakes in the U.S. and Spain were 
158 mg/d and 32 mg/d, respectively [26,27]. Low tea and red 
wine consumption in Korean adults may be attributed to their 
low intakes of flavan-3-ols.
Flavan-3-ols intake was inversely associated with the risk of 
MetS in female subjects, particularly with respect to hypertension. 
Green tea is the main dietary source of catechins gallates, and 
gallocatechins. Several epidemiological studies have reported the 
protective effects of green tea consumption against cardiovascular 
disease risk [13-15]. Chronic human intervention trials reported 
vasodilation effects of green tea and green tea extract [28,29]. 
Green tea consumption for two weeks showed a significant 
improvement in flow-mediated dilatation (FMD) assessed vascular 
reactivity among twenty smokers [28]. In a study by Tinahones 
et al., a group who consumed green tea extract showed higher 
vasodilation effects than a placebo group [29]. Several animal 
studies have also reported the beneficial vascular functions of 
green tea extract and EGCG [30-32]. Fruits, red wine, cocoa, 
and black tea also have been reported to reduce the risk of MetS 
or MetS components in many research settings including cohort 
studies, clinical trials, and cross-sectional studies [16-19].
The possible mechanisms underlying the impact of flavan-3-ols 
on vascular function are explained as follows. EGCG activates 
endothelial NO synthase (eNOS) in rat aortic rings [33]. It was 
also proposed that catechins may help regulate NADPH oxidase 
activity by reducing O2
- production, which results in the 
protection of NO from peroxynitrite formation [34]. Increased 
NO bioavailability may explain the improvements in endothelial 
function (blood pressure). Since insulin sensitivity is, at least in 
part, dependent on nitric oxide bioavailability, flavan-3-ols may 
simultaneously improve insulin sensitivity as well as vascular 
function. Catechins and theaflavins prevented hyperglycaemia by 
enhancing insulin sensitivity and by decreasing pancreatic β-cell 
damage in an animal study [35]. Another plausible mechanism 
is that EGCG increases prostacyclin (PGI2) production which is 
known as a potent vasodilator. EGCG dose-dependently increased 
PGI2 production in bovine endothelial cells [36]. Flavan-3-ols 
from fruits improved indices of MetS in animal models [37], 
but more studies examining flavan-3-ols from fruits are needed.
The effects of flavan-3-ols on MetS were different by obesity. 
In the male subjects, flavan-3-ols intake was inversely related 
to the risk of hypertension only in non-obese men. Among the Yoon Jung Yang et al. 73
Quintiles
P-for trend
Q1 Q2 Q3 Q4 Q5
Male
1)
  Metabolic syndrome 
    Model 1 1.00 (ref) 1.12 (0.78, 1.60) 0.92 (0.64, 1.33) 0.86 (0.60, 1.25) 0.86 (0.60, 1.24) 0.314
    Model 2 1.00 (ref) 1.02 (0.71, 1.48) 0.85 (0.58, 1.25) 0.83 (0.57, 1.21) 0.84 (0.58, 1.22) 0.449
    Model 3 1.00 (ref) 1.06 (0.73, 1.53) 0.90 (0.62, 1.32) 0.88 (0.60, 1.28) 0.92 (0.62, 1.34) 0.701
Components of the metabolic syndrome
  High blood pressure 
    Model 1 1.00 (ref) 1.01 (0.73, 1.38) 0.71 (0.51, 0.99) 0.71 (0.51, 0.99) 0.74 (0.54, 1.03) 0.200
    Model 2 1.00 (ref) 0.99 (0.72, 1.37) 0.71 (0.50, 0.99) 0.70 (0.50, 0.98) 0.73 (0.52, 1.02) 0.203
    Model 3 1.00 (ref) 1.01 (0.73, 1.39) 0.73 (0.52, 1.02) 0.72 (0.51, 1.00) 0.75 (0.53, 1.06) 0.263
  Hyperglycaemia 
    Model 1 1.00 (ref) 0.97 (0.70, 1.35) 0.85 (0.61, 1.18) 0.81 (0.58, 1.13) 0.90 (0.65, 1.26) 0.852
    Model 2 1.00 (ref) 0.89 (0.64, 1.24) 0.79 (0.56, 1.12) 0.76 (0.54, 1.07) 0.85 (0.60, 1.19) 0.813
    Model 3 1.00 (ref) 0.89 (0.64, 1.24) 0.78 (0.55, 1.10) 0.75 (0.54, 1.06) 0.84 (0.59, 1.19) 0.835
  Abdominal obesity 
    Model 1 1.00 (ref) 1.27 (0.79, 2.06) 1.07 (0.66, 1.75) 1.13 (0.70, 1.84) 1.03 (0.64, 1.66) 0.660
    Model 2 1.00 (ref) 1.16 (0.71, 1.90) 1.02 (0.62, 1.69) 1.13 (0.69, 1.85) 0.99 (0.61, 1.61) 0.670
    Model 3 1.00 (ref) 1.18 (0.72, 1.93) 1.04 (0.62, 1.72) 1.14 (0.69, 1.87) 0.98 (0.59, 1.61) 0.587
  Low HDL cholesterol
    Model 1 1.00 (ref) 1.02 (0.75, 1.40) 1.25 (0.91, 1.72) 1.23 (0.90, 1.69) 1.24 (0.90, 1.69) 0.360
    Model 2 1.00 (ref) 1.02 (0.74, 1.40) 1.19 (0.86, 1.64) 1.23 (0.89, 1.69) 1.26 (0.91, 1.74) 0.247
    Model 3 1.00 (ref) 1.05 (0.76, 1.44) 1.24 (0.90, 1.72) 1.30 (0.94, 1.80) 1.38 (0.99, 1.93) 0.113
  Hypertriglyceridaemia
    Model 1 1.00 (ref) 1.18 (0.86, 1.60) 1.06 (0.77, 1.45) 1.15 (0.84, 1.57) 1.05 (0.77, 1.44) 0.808
    Model 2 1.00 (ref) 1.10 (0.80, 1.50) 1.00 (0.72, 1.38) 1.12 (0.81, 1.54) 1.03 (0.75, 1.43) 0.950
    Model 3 1.00 (ref) 1.11 (0.81, 1.52) 1.03 (0.74, 1.42) 1.14 (0.83, 1.58) 1.04 (0.75, 1.45) 0.895
Female
2)
  Metabolic syndrome 
    Model 1 1.00 (ref) 0.57 (0.41, 0.79) 0.60 (0.43, 0.83) 0.60 (0.43, 0.83) 0.58 (0.42, 0.81) 0.166
    Model 2 1.00 (ref) 0.59 (0.43, 0.82) 0.63 (0.45, 0.88) 0.63 (0.45, 0.88) 0.62 (0.44, 0.87) 0.274
    Model 3 1.00 (ref) 0.60 (0.43, 0.83) 0.65 (0.46, 0.91) 0.65 (0.46, 0.91) 0.64 (0.45, 0.91) 0.384
Components of the metabolic syndrome
  High blood pressure 
    Model 1 1.00 (ref) 0.93 (0.69, 1.25) 0.81 (0.59, 1.10) 0.86 (0.63, 1.17) 0.55 (0.40, 0.76) 0.0003
    Model 2 1.00 (ref) 0.94 (0.70, 1.28) 0.85 (0.62, 1.17) 0.90 (0.66, 1.23) 0.57 (0.41, 0.79) 0.0006
    Model 3 1.00 (ref) 0.99 (0.73, 1.34) 0.92 (0.67, 1.26) 0.97 (0.70, 1.33) 0.64 (0.45, 0.90) 0.005
  Hyperglycaemia 
    Model 1 1.00 (ref) 0.82 (0.62, 1.10) 0.86 (0.64, 1.15) 0.87 (0.65, 1.16) 0.79 (0.59, 1.06) 0.334
    Model 2 1.00 (ref) 0.83 (0.62, 1.10) 0.89 (0.66, 1.19) 0.90 (0.67, 1.21) 0.82 (0.61, 1.10) 0.428
    Model 3 1.00 (ref) 0.84 (0.63, 1.12) 0.90 (0.67, 1.21) 0.92 (0.69, 1.24) 0.85 (0.63, 1.16) 0.616
  Abdominal obesity 
    Model 1 1.00 (ref) 1.10 (0.75, 1.61) 0.91 (0.61, 1.36) 0.99 (0.67, 1.49) 1.14 (0.77, 1.69) 0.436
    Model 2 1.00 (ref) 1.12 (0.76, 1.64) 0.89 (0.60, 1.34) 1.01 (0.68, 1.51) 1.21 (0.81, 1.80) 0.274
    Model 3 1.00 (ref) 1.13 (0.76, 1.66) 0.88 (0.59, 1.33) 1.01 (0.67, 1.52) 1.14 (0.75, 1.73) 0.466
  Low HDL cholesterol
    Model 1 1.00 (ref) 0.96 (0.75, 1.22) 0.96 (0.75, 1.22) 0.84 (0.66, 1.06) 0.83 (0.66, 1.06) 0.129
    Model 2 1.00 (ref) 0.99 (0.78, 1.26) 0.99 (0.78, 1.27) 0.88 (0.69, 1.13) 0.87 (0.68, 1.12) 0.202
    Model 3 1.00 (ref) 0.99 (0.78, 1.26) 1.00 (0.78, 1.28) 0.88 (0.69, 1.13) 0.86 (0.67, 1.11) 0.169
  Hypertriglyceridaemia
    Model 1 1.00 (ref) 0.72 (0.54, 0.96) 0.69 (0.51, 0.92) 0.71 (0.53, 0.94) 0.73 (0.55, 0.97) 0.442
    Model 2 1.00 (ref) 0.73 (0.55, 0.96) 0.70 (0.53, 0.94) 0.71 (0.53, 0.95) 0.74 (0.55, 0.99) 0.475
    Model 3 1.00 (ref) 0.73 (0.55, 0.97) 0.71 (0.53, 0.96) 0.72 (0.54, 0.97) 0.75 (0.56, 1.02) 0.612
Q ,  q u i n t i le ;  H D L ,  h ig h - d e n s i t y  l ip o p r o t e in
1) Model 1; adjusted for age, body mass index, Model 2; adjusted for all variables in model 1 plus education (elementary, middle, high, college), current smoking (yes/past/no), 
regular  exercise  (yes/no),  functional  food  use  (yes/no),  Model  3;  adjusted  for  all  variables  in  model  2  plus  intakes  of  total  energy,  fat,  and  fiber.
2) Model 1; adjusted for age, body mass index, Model 2; adjusted for all variables in model 1 plus education (elementary, middle, high, college), current drinking (more than 
once  a  month/none),  vitamin/mineral  supplement  use  (yes/no),  functional  food  use  (yes/no),  Model  3;  adjusted  for  all  variables  in  model  2  plus  intakes  of  total  energy, 
fat,  fiber,  and  carbohydrate
Table 4. Adjusted odd radios (ORs), and 95% confidence intervals (CIs) of MetS and MetS components by quintiles of flavan-3-ols intake74 Flavan-3-ols intake and metabolic syndrome
Fig. 1. Adjusted ORs and 95% CIs of MetS and MetS components by quintiles of flavan-3-ols in males according to obesity after adjusting for age, BMI, education 
(elementary, middle, high, college), current smoking (yes/past/no), regular exercise (yes/no), functional food use (yes/no), and intakes of total energy, fat, and fiber.
female subjects, the beneficial effects of flavan-3-ols on MetS 
were shown in only obese women. These results suggest that 
the effects of flavan-3-ols on MetS may be different depending 
on body fat composition. We could not find a previous study 
that compared the effects of flavan-3-ols by gender or weight 
status. Further studies on the effects of flavan-3-ols in normal, 
overweight, and obese subjects by gender are necessary. 
The limitations of this study need to be considered when 
interpreting the findings. Since it was a cross-sectional study, 
we cannot conclude a causality of flavonoid intake and MetS. 
Due to large intra-individual variability in food and nutrient 
intakes of most people, a one-day 24 hr dietary recall is not Yoon Jung Yang et al. 75
Fig. 2. Adjusted ORs and 95% CIs of MetS and MetS components by quintiles of flavan-3-ols in females according to obesity after adjusting for age, BMI, education 
(elementary, middle, high, college), current drinking (more than once a month/none), vitamin/mineral supplement use (yes/no), functional food use (yes/no), and intakes
of total energy, fat, fiber, and carbohydrate.
sufficient to estimate usual daily flavan-3-ols intake. Since a 
national nutrient database on flavonoids is not available in Korea, 
we constructed a flavonoid database using the USDA Flavonoid 
Database [22], the Japan Functional Food Factor Database [23], 
and the Rural Development Administration Food Functional 
Composition Table [24], which covered 85% of plants foods and 
96% of the most commonly consumed foods in the 2008 
KNHANES. Missing flavan-3-ols values in the database would 
have decreased the estimation of flavan-3-ols intake. Moreover, 
there is large variability in the flavonoid content of foods 76 Flavan-3-ols intake and metabolic syndrome
depending on cultivating season and methods, geographical 
origin, and processing; thus, the flavonoid contents of foods 
commonly consumed by Koreans need to be analyzed in further 
studies. 
Despite these limitations, the results of this study suggest that 
flavan-3-ols intake may have beneficial effects on MetS, 
particularly by reducing the risk of hypertension. These beneficial 
effects may be different between non-obese and obese 
individuals. Further investigations including clinical trials and 
cohort studies are required to confirm these findings.
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